CapMan Buyout has exited its investment in Pharmia by selling the Finnish contract manufacturer to Labomar, enhancing Labomar's capabilities in the Nordic dietary supplements and medical devices market.

Target Information

Funds managed by CapMan Buyout have successfully exited their investment in Pharmia Holding Oy, a premier Finnish contract manufacturer specializing in dietary supplements and medical devices, by selling the company to Labomar. CapMan initially invested in Pharmia in 2021 and meticulously focused on enhancing the company's operational capabilities and market presence within the Nordic region. Under CapMan's stewardship, Pharmia has established itself as the foremost contract manufacturer in its sector in the Nordics, achieving a turnover of approximately 20 million euros and employing around 85 professionals.

The growth trajectory of Pharmia has been significantly supported by a strategic emphasis on advancing its offerings in medical devices and probiotics. Investment in research and development, along with improvements in operational efficiencies, has played a pivotal role in this journey.

Industry Overview in Finland

The dietary supplements and medical devices industry in Finland operates within a rapidly evolving landscape, characterized by an increasing consumer focus on health and wellness. As awareness around preventative health measures rises, the demand for high-quality supplements